Tolerance through Education: How Tolerogenic Dendritic Cells Shape Immunity

Matthias P. Domogalla1,2*, Patricia V. Rostan1,2, Verena K. Raker1,2 and Kerstin Steinbrink1,2

1 Department of Dermatology, Division for Experimental and Translational Research, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany, 2 Research Center for Immunotherapy, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany

Dendritic cells (DCs) are central players in the initiation and control of responses, regulating the balance between tolerance and immunity. Tolerogenic DCs are essential in the maintenance of central and peripheral tolerance by induction of clonal T cell deletion and T cell anergy, inhibition of memory and effector T cell responses, and generation and activation of regulatory T cells. Therefore, tolerogenic DCs are promising candidates for specific cellular therapy of allergic and autoimmune diseases and for treatment of transplant rejection. Studies performed in rodents have demonstrated the efficacy and feasibility of tolerogenic DCs for tolerance induction in various inflammatory diseases. In the last years, numerous protocols for the generation of human monocyte-derived tolerogenic DCs have been established and some first phase I trials have been conducted in patients suffering from autoimmune disorders, demonstrating the safety and efficiency of this cell-based immunotherapy. This review gives an overview about methods and protocols for the generation of human tolerogenic DCs and their mechanisms of tolerance induction with the focus on interleukin-10-modulated DCs. In addition, we will discuss the prerequisites for optimal clinical grade tolerogenic DC subsets and results of clinical trials with tolerogenic DCs in autoimmune diseases.

Keywords: tolerogenic dendritic cells, regulatory T cells, immunotherapy, tolerance, nanoparticles

INTRODUCTION

The antigen-specific induction of immunological tolerance in the context of autoimmune and allergic diseases, which are driven by undesired immune responses against the body's own or foreign antigens, has long been described as ultimate solution for the treatment of excessive immune activation. Nowadays, common treatment options are life-long, systemic immune suppression, which however may lead to serious side effects like chronic infections or malignant transformation. Therefore, various cell types have been investigated to establish permanent antigen-specific immune tolerance toward the causative triggers. Dendritic cells (DCs) as key players in controlling immune responses by either inducing immunity or establishing tolerance through interaction with multiple immune cells seem to be excellent candidates for the re-establishment of permanent antigen-specific tolerance. Since their discovery in 1973 by Ralph M. Steinman, several in vitro protocols have been established for the generation of potent, stable tolerogenic DCs whereof some have recently been used for the treatment of transplantation rejection, autoimmune and allergic disorders in vivo. In addition, to avoid ex vivo generation and modulation of DCs, DC-specific in vivo targeting, e.g., by antibodies or nanoparticle-based approaches, which can directly deliver immunomodulatory drugs...
to DCs, have emerged as a promising tool. In this review, we will outline the different protocols for generation of tolerogenic DCs, their mechanisms of tolerance induction, and summarize their use in preclinical and clinical settings.

**ROLE OF DCs IN IMMUNITY AND TOLERANCE**

Recognition of DCs as professional antigen-presenting cells has come a long way. Antonio Lanzavecchia once stated that DCs seemed “too rare to be relevant” (1). With the Steinman lab pioneering DC immunology in the 1980s, the field started to expand rapidly and apart from their function in induction and maintenance of immunity, they also became relevant as promising candidates for immunotherapy with regards to tolerance induction.

Some refer to DCs as “nature’s adjuvants” highlighting their central role in the induction of immune responses. DCs populate almost all body surfaces in order to serve as sentinels detecting pathogens either by membrane-bound toll-like receptors (TLRs) or within the cytosol through nucleotide-binding oligomerization domain-like receptors (NLR) (2, 3). They do not kill the pathogen directly but use an even more sophisticated approach that induces long-lasting antigen-specific responses sufficiently bridging innate and adaptive immunity. By utilizing a proteolytic machinery (endolysosomal and proteosomal), they partially degrade antigens to peptides to subsequently display peptide/major histocompatibility (MHC) complexes on their surface (4). Although other cells such as macrophages and B cells are also able to present antigens via MHC, DCs are the only cell type to activate naive T cells and to induce antigen-specific immune responses in all adaptive immune cells (4). They can for instance directly induce antibody production by presenting intact antigen to antigen-specific B cells without engaging T cells (5). DCs take a guiding role in immune responses as they interrogate, interpret, and transmit the nature of the antigenic stimulus, thereby shaping even T cell polarization via different intracellular signaling pathways (6).

Immature DCs (iDCs) are predominantly found in the peripheral tissues where they patrol and extensively take up large quantities of membrane-bound or soluble antigen by macrophagy and phagocytosis. However, at an immature state, DCs are inefficient in displaying MHC/peptide complexes on their surface as, e.g., their lysosomal activity is attenuated (3). The ability to channel MHC/peptide complexes to the surface increases upon engagement of pathogen recognition receptors such as TLRs or NLRs, which drive DC maturation (7). DCs change their capacity from antigen accumulation to T cell activation within only 1 day. Expression of chemokine receptors (C–C chemokine receptor (CCR) 1, CCR2, CCR5, CCR6, and C–X–C chemokine receptor (CXCR) 1) facilitates immature DC recruitment to the site of inflammation. Activation of DCs results in CCR6 downregulation and CXCR7 and CXCR4 upregulation directing DCs toward the lymph node (8, 9).

Dendritic cell maturation, however, has a high degree of plasticity meaning that differentiated mature DCs (mDCs) can easily convert to tolerogenic DCs. This has been shown, e.g., by a group that stimulated activated DCs with pro-inflammatory interferon-γ (IFN-γ), which promoted the expression of indoleamine 2,3-dioxygenase (IDO) leading the respective DCs to acquire tolerogenic potential (10).

The original concept of tolerance induction by DCs is attributed to low amounts of surface MHC and co-stimulatory molecules such as cluster of differentiation (CD) 80 and CD86 found on iDCs. In contrast, the CD80/CD86<sup>+</sup> expressing mature DC counterpart would rather activate effector T cells. However, in an uninfected individual, maintenance of self-tolerance is ensured by a continuous input of short-lived DCs that provide self-antigens in the lymphatic tissues. Notably, DCs isolated in the cold from germ-free mice show expression of co-stimulatory molecules and activate T cells to enter cell cycle (11). This indicates that the original view of tolerance induction is highly dependent on DCs’ mutual state of development and activation, as well as the surrounding microenvironment of cytokines and growth factors.

Dendritic cells in the thymus establish (central) self-tolerance by the display of self-antigens to developing T cells inducing T cell negative selection or Treg differentiation (12). Induction of peripheral T cell anergy and apoptosis, attenuation of effector and memory T cell responses, and the generation and activation of regulatory T cell (Treg) subpopulations has been attributed to a variety of tolerogenic DC subtypes (13–16).

Dendritic cell subtypes in humans can be characterized by anatomical localization and respective function. In steady state, blood DCs are immature precursors of tissue or lymphoid organ DCs. Epithelial tissues contain non-lymphoid or migratory DC subtypes (17). Lymphoid tissues harbor resident DC populations, which lack migratory capacities and play a role in retrieval of antigen and maintenance of antigen-specific immune responses (e.g., follicular DCs that recycle and “store” antigen for prolonged B cell activation in lymph node germinal centers) (18). Upon pathogen encounter and subsequent inflammatory state, the DC content of tissue and lymphoid organs is altered. Steady state DCs are diluted by CD14<sup>+</sup> classical monocytes and precursors of inflammatory DCs. Blood DCs might also enter tissues via CD62 ligand (L) and CXCR3 expression, which allows extravasation (19).

Site-specific appearance contaminating monocytes/macrophages and diverse inflammatory stimuli hinder a distinct phenotypical characterization of DC subsets. However, DCs were originally defined by their characteristic dendritic morphology and extraordinary capacity for antigen presentation and T cell priming (20, 21). These classical or conventional DCs (cDCs) are now classified into two main subsets, the CD11b<sup>+</sup> and CD8<sup>+</sup>/CD103<sup>+</sup> cDCs in mice and the corresponding blood dendritic cell antigen (BDCA)-1<sup>+</sup> (CD1c<sup>+</sup>) and BDCA-3<sup>+</sup> (CD141<sup>+</sup>) cDCs in humans. Beyond these subsets, however, a significant functional, genetic, and phenotypic diversity of DCs has been recently appreciated. There have been huge recent efforts by the scientific community to identify strategies in order to align DC phenotypes in a tissue and cross-species specific manner via flow cytometry. A set of lineage-imprinted markers recently published by Guilliams et al. is sufficient to differentiate between human plasmacytoid DCs (pDC: CD45<sup>+</sup>CD11c<sup>low</sup> human leukocyte antigen-D related (HLADR)<sup>+</sup> interferon response factor (IRF)
Figure 1: Flow cytometric phenotyping of dendritic cells (DCs) aligned across tissues. Surface marker expression of human and mouse DCs in a variety of tissues was defined previously by Guilliams et al. (22) for cDC1s and conventional type 2 DCs (cDC2s). To identify DC subpopulations, a multi-color FACS staining, FSC/SSC pre-gating, and lineage (lymphocytes and NK cells) as well as macrophage exclusion has to be performed. If applicable for the desired tissue, afterward, CD45 immune cells are gated for CD1a high/CD172a low/CD11c mid-high as cDC1s or CADM1 high/CD172a high/CD1c high/CD11c high cDC2s. In humans and mice, DC cell fate can be additionally identified on the level of transcription factors: DCs in general are dependent on flt-3. cDC1 development depends on BATF3 and high levels of IRF8, whereas cDC2 evolution is dependent on IRF4 but independent of BATF3.

A sophisticated identification strategy will allow for a more profound analysis of DC fates in mice and humans with regard to immunological functions of DCs in immunity and tolerance.

**GENERATION AND SUPPRESSIVE MECHANISMS OF TOLEROGENTIC DCs**

During classical immune responses, after encountering an antigen in combination with a danger signal, DCs upregulate the expression of co-stimulatory molecules, lymph node-homing receptors plus MHC molecules, and start the secretion of pro-inflammatory cytokines (21). Those processes enable DCs to migrate to the lymph nodes and initiate the activation of naive T cells. Full T cell activation requires a three step signaling process. First, the binding of the T cell receptor (TCR) to its cognate antigen, which is presented on MHC molecules, second, the engagement of CD28 with co-stimulatory molecules like members of the B7 protein family CD80 and CD86, and third, interaction of DC-secreted cytokines with appropriate respective cytokine receptors (23).

In contrast, tolerogenic DCs exploit several immunosuppressive mechanisms to induce tolerance (Figure 2). Tolerogenic DCs often display an immature or semi-mature phenotype that is characterized by low expression of co-stimulatory and MHC molecules and altered cytokine production. Presentation of low levels of antigen without co-stimulation leads to T cell anergy (24) and promotion of regulatory T cell differentiation in vitro and in vivo (25–27). TCR signaling in combination with co-stimulation results in activation of the transcription factors nuclear factor of activated T cells (NFAT), activator protein (AP)-1, and nuclear factor “kappa-light-chain-enhancer” of activated B-cells (NF-κB) that subsequently induce a transcriptional program resulting in T cell activation (28). It is not yet exactly clear how absence of co-stimulation results in a transcription profile that...
Immunosuppressive mechanisms of tolerogenic dendritic cells (DCs). Immunosuppressive mechanisms of tolerogenic DCs include secretion of immunomodulatory mediators, like interleukin (IL)-10 and transforming growth factor-β (TGF-β), or retinoic acid, resulting in induction of tolerogenic DCs, inhibition of effector T cell function, and Treg generation. In addition, absence or reduction of major histocompatibility and co-stimulatory molecules is involved in induction of anergic T cells with regulatory capacity. Furthermore, expression of immune-modulatory/-inhibitory molecules like PDL-1/-2, CTLA-4, and ILT-3/4 or expression of death receptors like TRAIL or FAS represent mechanisms to inhibit efficient T cell responses by tolerogenic DCs. In addition, deprivation of nutrition factors by the expression of indoleamine 2,3-dioxygenase (IDO) and heme oxygenase-1 (HO-1) results in reduced T cell proliferation and Treg induction, respectively. In a similar way, shedding of soluble CD25 leads to IL-2 deprivation and reduced T cell proliferation.

Tolerogenic DCs may also express various inhibitory receptors like for example programmed cell death ligand (PDL)-1, PDL-2 (40, 41), inhibitory Ig-like transcripts (ILT) (42, 43), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (44), which act on T cells by dampening TCR signaling and competing with CD28, respectively. Tolerogenic DCs also alter T cell responses by modulation of metabolic parameters for example by the release of IDO and the induction of heme oxygenase-1 (HO-1) to control levels of tryptophan and carbon monoxide. IDO facilitates the degradation of tryptophan to N-formylkynurenin leading to reduced T cell proliferation (45, 46), whereas HO-1 inhibits hemoglobin, resulting in production of carbon monoxide, which leads to reduced DC immunogenicity (47, 48). In addition, tolerogenic DCs are also capable of producing retinoic acid (RA) (49), inducing Treg differentiation (50). Shedding of CD25 by DCs and subsequent deprivation of IL-2 was recently favored by Treg induction but impaired CD28-induced activation of the rat sarcoma/mitogen activated protein kinase (Ras/MAPK) pathway results in deficient AP-1 activation. In the absence of AP-1, NFAT proteins, possibly in combination with other transcription factors or by forming dimers, may subsequently initiate a transcriptional program that cumulates in T cell anergy and Treg induction (29). However, recent studies demonstrated that phenotypically mDCs are also capable of inducing Tregs, indicating that the phenotype does not necessarily determine the immunogenic or regulatory function of DCs (13, 30, 31). Furthermore, secretion of anti-inflammatory cytokines like interleukin (IL)-10 and transforming growth factor-β (TGF-β) and reduced expression of pro-inflammatory cytokines by DCs critically contribute to tolerance induction. Production of IL-10 by tolerogenic DCs is indispensable for regulatory function in multiple settings (32–34) and DC-released TGF-β is important for tolerance induction as DC-specific ablation of the TGF-β activating integrin αvβ8 (Itgb8) results in autoimmunity and colitis as demonstrated in transgenic CD11c-Cre/Itgb8<sup>fl/fl</sup> mice (35). Moreover, TGF-β secretion by tolerogenic DCs is important for the regulation of Th<sub>17</sub> responses in neuro-inflammation as shown in CD11c<sup>Cre</sup> mice, which is a dominant-negative form of TGF-β receptor II resulting in diminished TGF-β signaling (36). Furthermore, IL-10 and TGF-β, which are secreted by tolerogenic DCs in the tumor microenvironment, facilitate and reinforce tumor escape (37). In addition, several immunosuppressive features of tolerogenic DCs rely on induction of apoptosis in responding T cells including Fas cell surface death receptor (FasL/Fas) interactions (38) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAILR engagement (39). Tolerogenic DCs may also express various inhibitory receptors like for example programmed cell death ligand (PDL)-1, PDL-2 (40, 41), inhibitory Ig-like transcripts (ILT) (42, 43), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (44), which act on T cells by dampening TCR signaling and competing with CD28, respectively. Tolerogenic DCs also alter T cell responses by modulation of metabolic parameters for example by the release of IDO and the induction of heme oxygenase-1 (HO-1) to control levels of tryptophan and carbon monoxide. IDO facilitates the degradation of tryptophan to N-formylkynurenin leading to reduced T cell proliferation (45, 46), whereas HO-1 inhibits hemoglobin, resulting in production of carbon monoxide, which leads to reduced DC immunogenicity (47, 48).
proposed as additional immunosuppressive mechanism for the suppression of effector T cell proliferation (13).

Several human tolerogenic DC subsets have been characterized *in vitro* based on their tolerogenic capacities. iDCs display minimal expression of co-stimulatory molecules and no secretion of inflammatory cytokines, demonstrating the aforementioned optimal requirements for tolerance induction, which has also been demonstrated *in vitro* (51). However, iDCs are unstable and may differentiate into immunogenic DCs under inflammatory conditions (13, 52).

Therefore, many protocols have been established to generate stable human DCs with tolerogenic capacities *in vitro* (Figure 3). The opportunity to genetically modify human DCs has been exploited to directly induce tolerogenic properties by the recombinant expression of FasL (53), PD-L1 plus TRAIL (54), or IDO (55) all of which lead to the induction of T cell apoptosis and suppression of effector T cell function, respectively. Additionally, DCs can genetically be engineered to secrete enhanced levels of IL-10 (56) or TGF-β (57) resulting in broad immunosuppression.

Furthermore, human tolerogenic DCs are induced by various immunosuppressive drugs (Figure 3) that are often systemically used to control excessive immune responses like corticosteroids, rapamycin, cyclosporine, or by acetylsalicylic acid (58). For instance, the corticosteroid dexamethasone is capable of inducing tolerogenic DCs that exhibit low expression of co-stimulatory molecules combined with highly expressed inhibitory receptors ILT-2 and ILT-3 and secrete large amounts of IL-10 and IDO resulting in the induction of T cells with regulatory capacities (15, 59–61). In a similar way, the immunosuppressive drug rapamycin, which inhibits mechanistic target of rapamycin persuades human DCs to express a stable tolerogenic phenotype with reduced expression of MHC and co-stimulatory molecules in combination with a high ILT-3 and ILT-4 expression, leading to Treg generation *in vitro* and *in vivo* (15, 59, 62–64). Furthermore, in the presence of acetylsalicylic acid, DCs downregulate the expression of co-stimulatory molecules, whereas inhibitory molecules like ILT-3 and PD-L1 are upregulated resulting in Treg induction (65).

In addition, incubation with the immunosuppressive cytokines TGF-β and IL-10 alone or in combination facilitated the generation of a tolerogenic DC phenotype (Figures 2–4) (48, 66). For instance, TGF-β dampens the antigen-presenting capabilities of DCs by downregulation of MHC and co-stimulatory molecules and upregulation of PDL-1 resulting in T cell anergy (15, 36, 59, 67, 68). The comprehensive tolerogenic properties of IL-10 induced tolerogenic DCs will be discussed in detail in the next chapter. However, other biderivates are also capable of inducing DCs with tolerogenic function (Figure 3). In the presence of hepatocyte growth factor, DCs express various tolerance-inducing...
molecules like IDO, IL-10, TGF-β and TRAIL, which may induce T cell with regulatory functions (48, 69). Furthermore, treatment of human DCs with vitamin D3 (VitD3) triggers a tolerance-inducing phenotype that is characterized by enhanced IL-10 secretion, augmented IDO production and the expression of PDL-1 and Trail. Resulting DC populations are either capable of inducing antigen-specific T cell apoptosis or expansion of Tregs (59, 60, 70–72). The immunoregulatory neuropeptide vasoactive intestinal peptide prevents full maturation of DCs and induces high IL-10 secretion (73). Furthermore, a recent study by Olivar et al. demonstrated tolerogenic capacities of human DCs that are generated in the presence of the complement factor H resulting in reduced expression of co-stimulatory molecules on DCs, enhanced IL-10 and TGF-β gene expression and induction of forkhead box P3 (FOXP3)+ Tregs (74).

Since a comparative study by Boks et al. in 2012 identified human IL-10-modulated tolerogenic DCs (IL-10 DCs) as the most potent candidates for antigen-specific induction of tolerance in vivo (15), their generation and suppressive mechanisms will be highlighted in the next chapter.

**MECHANISM OF TOLERANCE INDUCTION BY HUMAN IL-10-MODULATED TOLERGENIC DCs**

Interleukin-10 DCs have been playing a pivotal and central role in the research field of tolerogenic DCs for over two decades. However, a variety of in vitro protocols exist for the generation of IL-10 DCs leading to a huge amount of data that are challenging to compare (Figure 4).

Interleukin-10-modulated DCs are usually generated from monocytes when cultured in the presence of IL-4 and GM-CSF to induce iDCs. The two most prominent protocols add IL-10 either during the whole culture (referred to as DC10s in the following) or at a later time point together with a maturation stimulus (referred to as IL-10 DCs) (13–15, 24, 75–79).

Gregori and colleagues generated DC10s using the first mentioned protocol and characterized them as CD14+ CD16+CD11c+CD40+HLA-DR+CD80+CD83+ CD86+CD163+ and CD1a+CD1c+CD68+CD115–MDC8 DCs. In contrast, mDCs are CD14– and CD16–, but express comparable amounts of CD80, CD83, CD86, and HLA-DR (77). It can be argued that the high expression of CD14 and CD16 indicate a macrophage-like phenotype (80). However, the lack of expression of the monocyte marker CD115 and the macrophage marker CD68 in combination with the constitutive expression of CD83, a DC-associated molecule, identified DC10s as immune cells of the DC lineage. Moreover, they show a DC-like morphology and are capable of driving naïve T cells to develop into antigen-specific Tr1 cells (77). DC10s also express the co-inhibitory molecules ILT-2, ILT-3, ILT-4, and HLA-G, and their capability to induce anergic Tr1 cells is ILT-4 dependent (77). Amodio et al. stated that the expression of HLA-G on DC10s is donor dependent and correlates with the expression of ILT-4 and with the frequency of Tr1 induction (78). These Tr1 cells are CD49b+ and LAG3+ and secrete high levels of IL-10, low IL-2, no IL-4, no IL-17, and variable amounts of IFN-γ (81–83). After LPS and IFNγ stimulation, mDCs and DC10s secrete comparable amounts of pro-inflammatory IL-6, but neither secrete the Th1-inducing cytokine IL-12, yet, DC10s produce slightly higher amounts of TNFα and considerably more IL-10 (77). The major function of tolerogenic DCs, the induction of Tregs, was found to be dependent on IL-10 secretion (77), similar to the upregulation of HLA-G on CD4+ T cells through stimulation with DC10s (78).

Gregori et al. have also identified the in vivo counterpart of the in vitro generated DC10s as naturally occurring DC10s in humans. They were sorted from peripheral blood from healthy volunteers as CD14+CD11c+CD83+ and analyzed for their poststimulation cytokine profile. In accordance with the findings from monocyte-derived DCs, their IL-12 secretion was negligible, but they produce relevant amounts of IL-6 and TNFα. Most importantly, their IL-10 levels were significantly increased compared to iDCs and mDCs (77).

![Figure 4](image-url)
A slightly different phenotype can be observed, when IL-10 DCs are generated using the latter previously mentioned protocol in which IL-10 is added for the last 2 days of the culture during the maturation step (Figure 4). Here, presence of IL-10 prevents full DC maturation, indicated by intermediate expression of the co-stimulatory molecules CD80 and CD86, as well as the DC maturation marker CD83 (13, 75). The tolerogenic phenotype is further established through the increased expression of the co-inhibitory molecules ILT-3 and ILT-4 (13, 15). This IL-10 triggered surface marker modulation is dependent on glucocorticoid-induced leucin zipper, a transmembrane molecule, which blocks NF-κB, MAPK, and AP-1 (84). The results for the expression of HLA-DR and CD14 on IL-10 DCs are contradictory. Our studies revealed that the whole IL-10 DC population shows an intermediate HLA-DR expression and that a subpopulation of IL-10 DCs are CD14- (24), whereas other groups found that HLA-DR expression is comparable to mDCs and IL-10 DCs are exclusively CD14- (85). In comparison with mDCs, IL-10 DCs stimulate a reduced T cell activation and are capable of inducing an antigen-specific anergy in CD4+ or CD8+ naïve T cells (24, 75, 76). The induction of anergy is associated with the increased expression of the MAPK p38 and its effector molecules MAPK-activated protein kinases 2 and 3 (86) as they upregulate the expression of the cyclin-dependent kinase inhibitor 1B (p27Kip1), leading to a cell cycle arrest in the G1 phase (79). The induced Tregs in turn have the ability to efficiently suppress syngeneic effector CD4+ and cytotoxic CD8+ T cells in a cell-to-cell contact-dependent and antigen-specific manner (15, 24, 79).

IL-10 DCs were identified as the most suitable candidate for DC-mediated tolerance-vaccination therapies as was shown by a comprehensive study by Boks et al. They compared five protocols for ex vivo induction of human tolerogenic DCs (through VitD3, dexamethasone, TGF-β, rapamycin, and IL-10) with regard to prerequisites for clinical applications in humans such as potent migratory capacity, sufficient Treg induction, and the stability of the tolerogenic phenotype under inflammatory conditions to guarantee the safety of the therapy (13, 15). The protocol using IL-10 for tolerogenic DC generation was shown to be superior as compared to the other tested protocols, with respect to the stability of the tolerogenic phenotype and the suppressive capacity of the induced Tregs (15). Boks et al. also revealed that co-maturation was indispensable for the stability of the phenotype and for the migratory capability in all protocols tested (15).

However, in their study, IL-10 DCs displayed a limited migratory capability due to a reduced CCR7 expression (15). This was confirmed by another comparative study by Adnan et al., which compared tolerogenic DC protocols in a similar way. However, they also showed that IL-10 DCs induce higher numbers of IL-10+CD4+ Tregs than tolerogenic DCs generated with other protocols [involving protein kinase C inhibitor (PKCI), VitD3, dexamethasone, TGF-β, rapamycin, and peroxisome proliferator-activated receptor γ + all-trans RA] and that the Tregs induced by both IL-10 and PKCI-treated tolerogenic DCs exhibited a higher suppressive capacity compared to Tregs induced by other tolerogenic DC protocols (13, 15, 59, 84, 85). In accordance with that, among all protocols tested by Boks et al., only IL-10 DC-induced Tregs exhibited a significantly enhanced suppressive function, compared to other tolerogenic DCs. Therefore, Boks et al. concluded that IL-10 DCs are the most suitable candidates for tolerogenic DC-based therapies for allergic and autoimmune diseases and transplantation rejections (15).

Recent investigations of our own laboratory refined this thesis by identifying two subpopulations of the human tolerogenic IL-10 DCs, distinguishable by the expression of CCR7 and CD83 (CD83highCCR7- and CD83lowCCR7+ IL-10 DCs) (13). Both IL-10 DC subsets were capable of inducing Tregs, but the CD83high IL-10 DC-induced Tregs exhibited a significantly enhanced suppressive capacity. It is evident from the proliferation, cytokine production, and surface makers that Tregs induced by CD83high IL-10 DCs exhibit a more activated phenotype compared to Tregs induced by CD83low IL-10 DCs. In addition, the tolerogenic phenotype of the CD83high IL-10 DC population was found to be extremely stable in the presence of IL-1β, IL-6, and TNFα, mimicking an inflammatory environment (13). In contrast to mDCs, IL-10 DCs and predominantly the CD83high subpopulation express increased amounts of membrane-associated and soluble CD25, the latter of which was found to play a role in the suppression of T cell proliferation (13). CD25 is known to exert seemingly contradicting functions: the membrane-bound molecule may be involved in the stimulation of T cells, whereas the soluble form attenuates T cell proliferation by trapping IL-2 (87, 88).

However, most importantly, dependent on their high expression of CCR7, the CD83high IL-10 DCs displayed a pronounced migratory capability that is superior to that of CD83low or unsorted IL-10 DCs (13, 81, 89). Therefore, in conclusion, the tolerogenic characteristics of the most promising population of tolerogenic DCs, IL-10 DCs can be further improved by sorting for CD83high IL-10 DCs.

**NANOPARTICLE-BASED IN VIVO INDUCTION OF TOLEROGENTIC DCs**

The above discussed protocols greatly expanded the knowledge of tolerogenic DC biology and enabled scientists to generate tolerogenic DCs that are stable under inflammatory conditions and may be used for antigen-specific clinical application. However, for this purpose, DC precursors need to be isolated from the patient’s blood, modulated ex vivo and re-injected into the patient, which is a time-consuming and expensive process. In addition, recent data suggest that monocyte-derived DCs, which are used in such immunotherapeutic approaches may rather be allocated to the family of monocytes, which have less T cell stimulatory capacities than DCs in vivo (90, 91). Therefore, nanoparticle-based drug delivery systems that enable directed cell-type specific targeting in vivo in combination with delivery of multiple drugs in one formulation have emerged as another promising approach in DC-based immunotherapy.

For cell type-specific targeting, nanoparticles can be chemically conjugated to antibodies, peptides, carbohydrates, or cytokines that address receptors that are preferentially expressed on DCs (92–95). For instance, targeting of human DCs in vivo with subsequent antigen presentation and robust humoral and cellular responses can be achieved by antibodies against the
c-type lectin receptor DEC205 as shown in a recent phase 1 clinical trial (96). In addition, other possible receptors that have been used to specifically target DCs include DC-SIGN, the mannose receptor, Fc receptors, CD40, or CD11c (93, 97, 98). Even though most approaches focus on induction of immunity for example in the context of tumor immunotherapy, cell-type-specific nanoparticle delivery is also a promising strategy to prevent excessive immune responses and induce DCs with tolerogenic capacity. For instance, polymeric synthetic nanoparticles that target DCs have been used to induce OVA-specific tolerance by delivery of rapamycin (99). In a similar approach, Zhang et al. were able to prevent antibody formation against substituted factor VIII (100). Intriguingly, Clemente-Casares et al. generated nanoparticles that target disease relevant peptides toward MHC II molecules, which subsequently trigger the expansion of antigen-specific Tr1 cells and regulatory B cells in different autoimmune disease models such as type 1-diabetes, inflammatory bowel disease, rheumatoid arthritis, and multiple sclerosis resulting in alleviation of disease symptoms (101).

USE OF TOLEROGIC DCs IN CLINICAL APPLICATIONS

Over the last decades, numerous trails with DC-based immunotherapies have been conducted using activated, mDCs to stimulate antitumor immune responses, and some have shown objective clinical benefits in patients with different types of cancer, including prostate cancer or malignant melanoma (102–104). Currently, several immunotherapeutic approaches are being studied using tolerogenic human DCs for treatment of inflammatory, autoimmune, and allergic diseases as well as transplant rejections (58, 105) (Figure 5).

In contrast to standard immunosuppressive therapies, which often do not specifically target the cause of disease and are accompanied by severe side effects, ex vivo generated tolerogenic DCs may be an attractive therapeutic approach to induce, enhance, or restore (antigen-specific) tolerance. After loading with exogenous or endogenous antigens, one major advantage of tolerogenic DC vaccination is their capability to act in an antigen-specific manner. Evidence from several rodent models clearly showed the efficacy of tolerogenic DCs in the fields of inflammatory, autoimmune, and allergic disorders and transplantation medicine (58, 105). To translate the results into the human system, several ex vivo studies have been performed as proof of principle experiments demonstrating that human tolerogenic DCs efficiently inhibit disease-related immune responses, e.g., by induction of Tregs or T cell anergy and apoptosis. With regard to allergic diseases, ex vivo models have shown that human tolerogenic IL-10 DCs from atopic donors suppressed Th2 immune responses by induction of FOXP3+ Tregs and dexamethasone-induced tolerogenic DCs activated IL-10 producing Tregs, specific for the latex Hev b 5 antigen, in rubber latex allergic patients (106, 107). Since tolerogenic DCs are also a promising tool to restore tolerance to specific tissue-derived autoantigens, several ex vivo studies have been conducted with tolerogenic DCs obtained from patients suffering from autoimmune disorders (58). Tolerogenic VitD3-treated DCs derived from precursor cells of multiple sclerosis patients and loaded with myelin peptides induced a stable and antigen-specific hyporesponsefulness of autologous T cells (58, 108), which was shown to be TGF-β-dependent (109). Studies in type 1 diabetes patients revealed that tolerogenic DCs, generated either in the presence of vitamin D or of IL-10/TGF-β, and loaded with the pancreatic islet antigen glutamic acid decarboxylase 65 rendered antigen-specific T cells hyporesponsive toward a second challenge with fully competent, antigen-loaded DCs (66, 110). Furthermore, monocyte-derived DCs were obtained from systemic lupus erythematosus (SLE) patients, treated with dexamethasone/rostiglitzzone and loaded with self-antigens. Those tolerogenic DCs can modulate CD4+ T cell activation and are a suitable tool for antigen-specific immunotherapy in SLE (111).

Although safety and feasibility of DC-based studies in general have already been shown, there are still a lot of open questions regarding the DCs manufacturing protocols, the route of application, the numbers of DCs, and the frequency and time points of injections. In addition, the characteristics of tolerogenic DCs, including the phenotype, migratory capacity, stability under inflammatory conditions, and the mode of action (induction/activation of regulatory T and B cells, T cell anergy and apoptosis induction, interaction with other immune cells) have to be investigated and different protocols have to be compared with regard to these properties. Aiming to joint efforts in translating tolerogenic DCs into the clinic by harmonizing protocols and defining functional quality parameters, international co-operations in science, and technology network have been initiated (112, 113).

One major concern in the context of tolerogenic DC-based immunotherapies is the stability of the tolerogenic phenotype.
under inflammatory conditions as DCs express several pattern-recognition receptors and receptors for growth factors and cytokines, which can be stimulated in an inflammatory environment. Therefore, clinical grade tolerogenic DCs must be intensively tested for a robust, stable phenotype to exclude a loss of the regulatory function and a switch to an immunostimulatory phenotype of the differentiated DCs, leading to an (antigen-specific) immune activation rather than to the intended immunosuppressive reaction. Comparative studies revealed that most of the tolerogenic ex vivo generated DC populations (by use of, e.g., IL-10, TGF-β, VitD3, rapamycin, dexamethasone, PKCl as described above), exhibit the aforementioned stable phenotype (15, 59). However, both reports demonstrated that tolerogenic IL-10 DCs showed the most powerful tolerogenic properties in terms of Treg induction with strong suppressive capacities. Another important feature is the CCR7-directed migratory capacity of tolerogenic DCs toward secondary lymphatic organs, resulting in the induction and generation of T cell-mediated immunosuppression. A recent study (as mentioned above) revealed that IL-10 DCs are consisting of two different populations, CD83highCCR7−/− IL-10 DC and CD83lowCCR7+− IL-10 DC subpopulations, both exhibiting tolerogenic properties, resulting in Treg induction (13). However, sorting of IL-10 DCs into these two subsets ascertained a significantly improved migratory capacity of the CD83highCCR7−/− IL-10 DC subpopulation compared to CD83lowCCR7+− IL-10 DCs, and to the non-separated IL-10 DC population as well. The stable phenotype, efficient CCR7-directed migration, and, in particular, pronounced tolerogenic capacity to induce Tregs with high suppressive activity of IL-10 DCs is a prerequisite for clinical grade DCs considered for vaccinations studies in humans.

Regarding the route of DC administration, different applications have been used in humans. Tolerogenic DCs have been injected intraperitoneally in patients suffering from Crohn’s disease (114), intradermally in diabetes, and rheumatoid arthritis patients (115, 116), subcutaneously in rheumatoid arthritis patients (117) and via arthroscopic injections in joints of patients with rheumatoid or inflammatory arthritis (118). In all studies, the route of administration has been well tolerated without any signs of toxicity. Likewise reports of intravenous injections of tolerogenic DCs into nonhuman primates revealed their safety (119).

The first attempt to apply tolerogenic DCs to humans was undertaken by Ralf Steinman’s group in 2001 (120, 121). They showed that subcutaneous applications of human immature tolerogenic DCs (2 × 106), generated in the presence of IL-4 and GM-CSF and pulsed with antigens, into healthy subjects was well tolerated and suppressed antigen-specific CD8+ T cell responses up to 6 months. Thus, they pioneered to demonstrate the tolerogenic potential of DCs in humans in vivo.

Several protocols for tolerogenic DCs have been tested in phase I trials with highly encouraging results from a safety point of view and in terms of adverse effects such as allergic reactions, exacerbations of autoimmunity, and pro-inflammatory immunity (114–118) (Table 1).

The first clinical trial with tolerogenic DCs was carried out in 10 patients suffering from diabetes type 1 in 2011. They were injected intradermally four times at 2-week intervals with 1 × 106 autologous DCs which have been either un-manipulated (controls) or have been treated with antisense oligonucleotides targeting CD40, CD80, and CD86 to silence these surface molecules. DC treatment was well tolerated without any adverse effects and did not induce autoantibody production (115). Analysis of the immune response revealed no alterations with exception of increased IL-4/IL-10 levels and elevated frequencies of a regulatory B220+CD11c+ B cell population. Importantly, the patients did not lose their ability to mount T cell responses, e.g., to pathogens, demonstrating the absence of a general immune suppression.

Another clinical trial was conducted to analyze the impact of tolerogenic DCs in nine patients suffering from Crohn’s disease (114). Here, under an escalating protocol tolerogenic, DCs (treated with dexamethasone and VitD3) were intraperitoneally injected in once or biweekly intervals, respectively. The DC vaccination was well tolerated and did not induce adverse effects from week 1 to 12 and in a follow-up up to 12 months.

In the field of rheumatoid arthritis, three trials have been published to date. In one study, 12 patients were subcutaneously injected with a low (0.5 × 106) or high dose (1.5 × 106) of autologous DCs for five times at 2- to 4-week intervals (117) (Table 1). The tolerogenic DCs were pulsed with protein arginine deiminase 4, heterogeneous nuclear ribonucleoprotein A2/B1 (RA33), citrullinated filaggrin, and vimentin antigens (=CreaVax-RA). The authors observed only a few patients with grade 1 or 2 adverse effects, but a combination of a significant decrease in autoantibody levels and a good-to-moderate EULAR response at 14 days after initiation of the trial, which was more pronounced in the DC high-dose group. Bell et al. reported the results of another dose escalation trial (AUTODEKRA trial) with rheumatoid arthritis patients who were intra-articularly treated with tolerogenic DCs (1 × 106, 3 × 106, or 10 × 106), generated in the presence of dexamethasone and VitD3 and loaded with autologous synovial fluid as source of autoantigens (118). No target knee flares and other severe side effects were observed. The authors did not find any trends in disease activity scores (DASs) or in consistent alteration of immune parameters in the peripheral blood; however, patients with the highest dose exhibited an improvement of the clinical symptoms.

In the study of Benham et al., tolerogenic DCs were generated in the presence of an NF-κB inhibitor, resulting in CD40 deficient but highly CD86 expressing tolerogenic DCs, which were administered to rheumatoid arthritis patients (116). For an antigen-specific immune response, DCs were pulsed with four different citrullinated peptide antigens (Rheumavax). 18 patients were injected intradermally with a single dose of the tolerogenic DCs (either 1 × 106 or 5 × 106). Evaluation of the patients after 1, 3, and 6 months revealed that the vaccination was well tolerated and no side effects in form of (auto-) inflammatory reactions have been observed. The authors found a reduction in effector T cells and several inflammatory mediators and an increased regulatory to effector T cell ratio in the patients. In addition, the DAS was decreased within 1 month in vaccinated patients with active rheumatoid arthritis, indicating the biological and clinical activity of this therapy.
Further phase I/II studies are under way in the fields of allergic diseases (allergic asthma), autoimmunity (Crohn’s disease, diabetes type 1, rheumatoid arthritis, and multiple sclerosis), and transplantation medicine (kidney transplantation) (https://clinicaltrials.gov).

A multitude of protocols has been developed to generate human tolerogenic DCs that can be tailored to induce specific tolerance. These innovative and attractive tools represent a promising therapeutic approach to treat inflammatory, autoimmune and allergic diseases, and transplant rejections. However, there is a high need to define optimal vaccination protocols and to identify the underlying immune mechanism of tolerance induction by human DCs in more detail. In this context, high-throughput approaches, e.g., in form of genomics and proteomics, will be of great help to analyze critical pathways contributing to programming and function of human tolerogenic DCs (122). Furthermore, next-generation tolerogenic DC vaccines should be integrated into future combinatorial immunotherapy regimes, including biologicals, nanoparticles, and in vivo targeting of DCs. So, it was demonstrated that combination of tolerogenic DCs with CTLA-4Ig strengthen their tolerogenic effect (123).

CONCLUSION

Dendritic cells are the most potent professional antigen-presenting cells of the immune system and bridge innate and adaptive immunity by interacting with a large number of different cell types, thereby initiating and regulating adaptive immune

---

### TABLE 1 | Use of tolerogenic dendritic cells in clinical applications.

| Study                        | Indication                | Patients | Protocol for tolDC | Antigen                                                                 | Treatment regime | Route of application | Summary                                                                 | Reference |
|------------------------------|---------------------------|----------|---------------------|------------------------------------------------------------------------|------------------|----------------------|------------------------------------------------------------------------|-----------|
| Phase I randomized controlled | Type 1 diabetes           | 10 (5/5 insulin-requiring type 1 diabetic patients) | 1. Un-manipulated 2. Antisense ODN targeting CD40, CD80, CD86 | No antigen                                              | $1 \times 10^7$ DC four times, every 2 weeks | Intradermal   | No adverse effects, increase of B220+ CD11c+ B cells, no change in other immune cell populations/biomarkers | (115)     |
| Phase I Rheumatoid arthritis | 12                        | CeaVax-retinoic acid (RA) | Protein arginine deminase 4, RA33, citrullinated filagrin, vimentin antigens | 0.5 or $1 \times 10^7$ or 1.5 or $2 \times 10^7$, five times at 2- to 4-week intervals | Subcutaneous   | Grade 1 or 2 adverse effects, significant decrease in antigen-specific autoantibodies (55.6%) and IFN-γ-secreting T cells (91.7%), EULAR response of 83.3% of patients injected with high dose | (117)     |
| Phase I randomized controlled | Rheumatoid arthritis      | 34 (18 treated/16 left untreated) HLA-DR risk genotype-positive RA patients | Bay 11-7082 (NF-κB inhibitor) | Citrullinated peptides: collagen type II fibrinogen α fibrinogen β vimentin | 0.5–1 or $2 \times 10^6$ or 2.0–4.5 or $1 \times 10^6$ one injection | Intradermal   | Grade 1 adverse effects, increased ratio of regulatory to effector T cells, reduction in serum IL-15, IL-29, CXCL1, and CXCL11; reduced antigen-specific T cell responses ($p < 0.05$) | (116)     |
| Phase I escalating Crohn's disease | 12 (2 per cohort) | Dexamethasone and vitamin A | No antigen | 2, 5, 10, or $10 \times 10^6$ once or three times (biweekly) in escalating doses | Intraperitoneal | No adverse effects, decrease in Crohn's Disease Activity Index (CDAI) ($p = 0.3$) and Crohn's Disease Endoscopic Index of Severity ($p = 0.4$), lesions improved markedly in three patients (33%) | (114)     |
| Phase I escalating randomized controlled | Rheumatoid arthritis | 12 [3 per treatment group (=9); saline control (=3)] | Dexamethasone and vitamin D3 | Autologous synovial fluid | $1 \times 10^7$, 3, 10, and $10 \times 10^6$ | Intracutaneous | Stabilized symptoms in two patients receiving $10 \times 10^6$ to IDC, but no decrease in disease activity score 26 detectable; no immunomodulatory effects | (118)     |
and nano-dimensional drug delivery may contribute to over-
protocols, genome editing, expression of recombinant proteins,
tion medicine. Progress in the fields of improved immunization
the therapy of allergic and autoimmune disease or in transplanta-
exhibiting numerous different mechanisms to dampen immune
ex vivo
objective to alleviate unwanted and excessive immune responses
clearance of pathogens or antitumor immunotherapy or for the
responses. Hence, DCs are promising targets for immunotherapy
in vivo,
which would be exceptionally beneficial for
the therapy of allergic and autoimmune disease or in transplanta-
therapy.

REFERENCES

1. Katsnelson A. Kicking off adaptive immunity: the discovery of dendritic
cells. J Exp Med (2006) 203:1622. doi:10.1084/jem.20571
2. Benko S, Magyarys Z, Szabo A, Rajnavolgyi E. Dendritic cell subtypes
as primary targets of vaccines: the emerging role and cross-talk of pattern
receptor recognition receptors. Biol Chem (2008) 389:469–85. doi:10.1515/
BC.2008.054
3. Zanoni I, Granucci F. Regulation of antigen uptake, migration, and lifespan
of dendritic cell by toll-like receptors. J Mol Med (2010) 88:873–80. doi:10.1007/
so0109-010-0638-x
4. Wilson NS, El-Sukkari D, Villadangos JA. Dendritic cells constitutively
present self antigens in their immature state in vivo and regulate antigen pre-
sentation by controlling the rates of MHc class II synthesis and endocytosis. 
Blood (2004) 103:2187–95. doi:10.1182/blood-2003-08-2729
5. Wykes M, MacPherson G. Dendritic cell-b-cell interaction: dendritic cells
provide B cells with CD40-independent proliferation signals and CD40-
deleted survival signals. Immunology (2000) 100:1-3. doi:10.1046/j.
1365-2567.2000.00044.x
6. Merad M, Sathie P, Helft J, Miller J, Mortha A. The dendritic cell lineage:
ontogeny and function of dendritic cells and their subsets in the steady state and
the inflamed setting. Annu Rev Immunol (2013) 31:563–604. doi:10.1146/
annurev-immunol-020711-074950
7. Drutmans SB, Trombetta ES. Dendritic cells continue to capture and present
antigens after maturation in vivo. J Immunol (2010) 185:2140–6. doi:10.4049/
immunol.1000642
8. Diczfalusy U, Vanbreuseghem T, Van den Bossche P, Van der Heyden M.
Dendritic cell maturation in vivo: effects of inflammatory cytokines on
endothelial cells and the blood circulation. J Immunol (2003) 171:5387–44.
doi:10.4049/jimmunol.171.10.5387
9. Sallusto F, Lanzavecchia A, Mackay CR. Chemokines and chemokine recep-
tors in T-cell priming and Th1/Th2-mediated responses. Immunity Today 
(1998) 19:568–74. doi:10.1016/S0167-5699(98)01346-2
10. Munn DH, Sharma MD, Lee JR, Jhaver KG, Johnson TS, Keskin DB, 
Morgan EG, et al. Potential regulatory function of human dendritic cells expressing
indoleamine 2,3-dioxygenase. Science (2000) 287:867–70. doi:10.1126/
science.1073514
11. Borrego A, Bernal E, Arias M, Del Pozo J. The role of dendritic cells in
the immune response to vaccination. J Investig Dermatol (2005) 125:939–43.
doi:10.1038/sj.jid.1102438
12. Perry JS, Lio CW, Kau AL, Nutsch K, Yang Z, Gordon JI, et al. Distinct
chemokines expressed in different anatomic sites. J Immunol (1998) 161:1889–96.
doi:10.4049/jimmunol.161.4.1889
13. Kershaw AJ, Kershaw TV, Gray SM, Rucker-Gray H, Tiemessen R. The
regulatory role of dendritic cells in the murine gut. J Immunol (2008) 180:1364–71.
doi:10.4049/jimmunol.180.2.1364
14. Raker VK, Domogalla MP, Steinbrink K. Tolerogenic dendritic cells for
regulatory T cell induction in man. Front Immunol (2015) 6:569. doi:10.3389/
immunol.2015.00569
15. Boks MA, Kager-Groenland JR, Haasjes MS, Zwangjing JF, van Ham SM, 
ten Brinke A. IL-10-generated tolerogenic dendritic cells are optimal for
functional regulatory T cell induction – a comparative study of human
clinical-applicable DC. Clin Immunol (2012) 142:332–42. doi:10.1016/j.
clinim.2011.11.011
16. Li H, Shi B. Tolerogenic dendritic cells and their applications in transplanta-
tion. Cytom Med Immunol (2015) 12:24–30. doi:10.3108/cmi.2014.52
17. Levin C, Perrin H, Combiadere B. Tailored immunity by skin antigen-presentation
cells. Hum Vacc Immunother (2015) 11:27-36. doi:10.4161/
hv.34299
18. Heesters BA, Chatterjee P, Kim YA, Gonzalez SF, Kuligowski MP, 
Kirschhausen T, et al. Endocytosis and recycling of immune complexes by
follicular dendritic cells enhances B cell antigen binding and activation. 
Immunity (2013) 38:1164–75. doi:10.1016/j.immuni.2013.02.023
19. Collin M, McGovern N, Haniﬁa M. Human dendritic cell subsets. 
Immunology (2013) 140:22–30. doi:10.1111/jimm.12117
20. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. 
Nature (1998) 392:245–52. doi:10.1038/23588
21. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 
(2007) 449:419–26. doi:10.1038/nature06175
22. Guilliams M, Dutertre CA, Scott CL, McGovern N, Sichien D, Chakarov S, 
et al. Unsupervised high-dimensional analysis aligns dendritic cells across 
tissues and species. Immunity (2016) 45:669–84. doi:10.1016/j.immuni. 
2016.08.015
23. Malissen B, Gregoire C, Malissen M, Roncagalli R. Integrative biology of
T cell activation. Nat Immunol (2014) 15:790–7. doi:10.1038/ni.2959
24. Steinbrink K, Graulich E, Kubisch S, Knop J, Enk AH, CD4(+) and CD8(+) anergic T cells induced by interleukin-10-treated human dendritic cells
display antigen-specific suppressor activity. Blood (2002) 99:2468–76.
doi:10.1182/blood.v99.7.2468
25. Kretschmer K, Apostolou I, Hawiger D, Khazaki E, Nussenweig M, 
von Boehm H. Inducing and expanding regulatory T cell populations by
foreign antigen. Nat Immunol (2005) 6:1219–27. doi:10.1038/nii265
26. Apostolou I, von Boehm H. In vivo instruction of suppressor commitment
in naive T cells. J Exp Med (2004) 199:1401–8. doi:10.1084/jem.20040209
27. Hermann-Kleiter N, Baire G. NFAT pulls the strings during CD4+ T
helper cell effector functions. Blood (2010) 115:2989–97. doi:10.1182/
blood-2009-10-233585
28. Hogan PG, Lewis RS, Rao A. Molecular basis of calcium signaling in lympho-
cytes: STIM and ORAI. Annu Rev Immunol (2010) 28:491–533. doi:10.1146/
annurev-immunol.021908.132350
29. Baine A, Bet AC, Macian F. Regulation of T-cell tolerance by calcium/NFAT
signaling. Immunity Rev (2009) 231:225–40. doi:10.1111/j.1600-065X.2009.
00817.x
30. Yamazaki S, Iyoda T, Tarbell K, Olson K, Velinzon K, Inaba K, et al. Direct
expansion of functional CD25(+) CD4(+) regulatory T cells by antigen-
processing dendritic cells. J Invest Dermatol (2003) 118:235–47. doi:10.1049/
immunol:20030422
31. Sousa CR. Essay – dendritic cells in a mature age. Nat Rev Immunol (2006) 
6:476–83. doi:10.1038/nri1845

FUNDING

This work was supported by the German Research Foundation (DFG): STE791/9-1, CRC 1066/8/B6, TR156 A4/C5, and by the German Cancer Aid (110631), and by intramural grants (all to KS). MD was supported by a fellowship of the Max Planck Graduate Center (MPGC) Mainz.
32. Wakkach A, Fournier N, Brun V, Brettmayer JP, Cottrez F, Groux H. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. *Immunity* (2003) 18:605–17. doi:10.1016/S1074-7613(03)00113-4

33. Akbari O, DeKruyff RH, Umetsu DT. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. *Nat Immunol* (2001) 2:275–31. doi:10.1038/90667

34. Travis MA, Reizis B, Melton AC, Masteller E, Tang Q, Proctor JM, et al. Loss of integrin alpha(v)beta8 on dendritic cells causes autoimmunity and colitis in mice. *Nature* (2007) 449:361–5. doi:10.1038/nature06110

35. Speck S, Lim J, Shelake S, Matka M, Stoddard J, Farr A, et al. TGF-beta signaling initiated in dendritic cells instructs suppressive effects on Th1 differentiation at the site of neuroinflammation. *PloS One* (2014) 9:e102390. doi:10.1371/journal.pone.0102390

36. Wakkach A, Fournier N, Brun V, Breittmayer JP, Cottrez F, Groux H. Potentiating differentiation of human induced regulatory T cells via STAT3 potentiates differentiation of human induced regulatory T cells via STAT3

37. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. *Annu Rev Immunol* (2007) 25:267–96. doi:10.1146/annurev.immunol.25.022106.141609

38. Keir ME, Francisco LM, Sharpe AH. PD-1 and its ligands in T-cell immunity. *Curr Opin Immunol* (2007) 19:309–14. doi:10.1016/j.coi.2007.04.012

39. Kurts C, Heath WR, Kosaka H, Miller JF, Carbone FR. The peripheral deletion of autoreactive CD8+ T cells induced by cross-presentation of self-antigens involves signaling through CD95 (Fas-Apo-1). *J Exp Med* (1998) 188:415–20. doi:10.1084/jem.188.3.415

40. Kurts C, Heath WR, Kosaka H, Miller JF, Carbone FR. The peripheral deletion of autoreactive CD8+ T cells induced by cross-presentation of self-antigens involves signaling through CD95 (Fas-Apo-1). *J Exp Med* (1998) 188:415–20. doi:10.1084/jem.188.3.415

41. Iwata M, Hirakiyama A, Eshima Y, Kagechika H, Kato C, Song SY. Retinoic acid imprints gut-homing specificity on T cells. *Handb Exp Pharmacol* (2000) 179:967–76. doi:10.1007/978-1-4615-438-1_14

42. Maldonado RA, von Andrian UH. How tolerogenic dendritic cells mediate tolerance induced by respiratory exposure to antigen. *Nat Immunol* (2001) 2:275–31. doi:10.1038/90667

43. Akbari O, DeKruyff RH, Umetsu DT. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. *Nat Immunol* (2001) 2:275–31. doi:10.1038/90667

44. Laurent S, Carrega P, Saverino D, Piccioli P, Camoriano M, Morabito A, et al. Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation. *Nat Rev Neurosci* (2007) 8:415–20. doi:10.1038/nrn21415

45. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. *Nat Rev Immunol* (2004) 4:762–74. doi:10.1038/nri1457

46. Curti A, Trabandelli S, Salvestrini V, Baccarani M, Lenotti RM. The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematologic malignancies. *Blood* (2009) 113:2394–401. doi:10.1182/blood-2008-07-144485

47. Chora AA, Fontoura P, Cunha A, Pais TF, Cardoso S, Ho PP, et al. Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation. *J Clin Invest* (2007) 117:438–47. doi:10.1172/JCI28844

48. Maldonado RA, von Andrian UH. How tolerogenic dendritic cells mediate T cell differentiation. *Adv Immunol* (2010) 108:111–65. doi:10.1016/B978-0-12-380995-7.00004-5

49. Iwata M, Hirakiyama A, Eshima Y, Kagechika H, Kato C, Song SY. Retinoic acid imprints gut-homing specificity on T cells. *Handb Exp Pharmacol* (2000) 179:967–76. doi:10.1007/978-1-4615-438-1_14

50. Wakkach A, Fournier N, Brun V, Breittmayer JP, Cottrez F, Groux H. Potentiating differentiation of human induced regulatory T cells via STAT3 potentiates differentiation of human induced regulatory T cells via STAT3

51. Wakkach A, Fournier N, Brun V, Breittmayer JP, Cottrez F, Groux H. Potentiating differentiation of human induced regulatory T cells via STAT3 potentiates differentiation of human induced regulatory T cells via STAT3

52. Wakkach A, Fournier N, Brun V, Breittmayer JP, Cottrez F, Groux H. Potentiating differentiation of human induced regulatory T cells via STAT3 potentiates differentiation of human induced regulatory T cells via STAT3

53. Kim SH, Bianco N, Menon R, Lechman ER, Shufesky WJ, Morelli AE, et al. Exosomes derived from genetically modified DC expressing Fasl are anti-inflammatory and immunosuppressive. *Mot Ther* (2006) 13:289–300. doi:10.1016/j.motthe.2005.09.015

54. Hirata S, Senju S, Matsuoyoshi H, Fukuma D, Uemura Y, Nishimura Y. Prevention of experimental autoimmune encephalomyelitis by transfer of embryonic stem cell-derived dendritic cells expressing myelin oligodendrocyte glycoprotein peptide along with TRAIL or programmed death-1 ligand. *J Immunol* (2005) 174:1888–97. doi:10.4049/jimmunol.174.4.1888

55. Bianco NR, Kim SH, Ruffner MA, Robbins PD. Therapeutic effect of exosomes from indoleamine 2,3-dioxygenase-positive dendritic cells in collagen-induced arthritis and delayed-type hypersensitivity disease models. *Arthritis Rheum* (2009) 60:380–9. doi:10.1002/art.24229

56. Lee WC, Qiani S, Wan Y, Li W, Xing Z, Gauldie J, et al. Contrast effects of myeloid dendritic cells transduced with an adenosvir vector encoding interleukin-10 on organ allograft and tumour rejection. *Immunology* (2000) 101:233–41. doi:10.1046/j.1365-2670.2000.00096.x

57. Yamazaki S, Bonito AJ, Spisek R, Dhodapkar M, Inaba K, Steinman RM. Dendritic cells are specialized accessory cells along with TGF-β for the differentiation of Foxp3+ CD4+ regulatory T cells from peripheral Foxp3 precursors. *Blood* (2007) 110:2493–302. doi:10.1182/blood-2007-05-088831

58. Garcia-Gonzalez P, Ubilla-Olguin G, Catalán D, Schimnerling K, Aguillon JC. Tolerogenic dendritic cells for reprogramming of lymphocyte responses in autoimmune diseases. *Autoimmun Rev* (2015) 14:1071–80. doi:10.1016/j.autrev.2014.12.032

59. Naton M, Forde M, Kayes N, Lin L, Allen BJ, Hwang JH, et al. Reverse transcription of tol4-induced Foxp3+ regulatory T cells from peripheral Foxp3+ regulatory T cells. *Blood* (2006) 108:218–27. doi:10.1182/blood-2005-08-3141
von Bergwelt-Baldon MS, Popov A, Saric T, Chemnitz J, Classen S, Stoffels MS, et al. CD25 and indoleamine 2,3-dioxygenase are up-regulated by progastaglin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood (2006) 108:228–37. doi:10.1182/blood-2005-08-3507

80. Boks MA, Kager-Groenland JR, van Ham SM, ten Brinke A, IL-10/IFN gamma co-expressing CD4+ T cells induced by IL-10 DC display a regulatory gene profile and downmodulate T cell responses. Clin Immunol (2016) 162:91–9. doi:10.1016/j.clim.2015.11.011

81. Guilliams M, Bruhns P, Saey S, Hammad H, Lambrecht BN. The function of Fcgamma receptors in dendritic cells and macrophages. Nat Rev Immunol (2014) 14:94–108. doi:10.1038/nri3582

82. Guilliams M, Ginhoux F, Jakubowski C, Naik SH, Onai N, Schraml BU, et al. Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. Nat Rev Immunol (2014) 14:571–8. doi:10.1038/nri3712

83. Lehmann CH, Heger L, Heidkamp GF, Baranska A, Luhr JJ, Hoffmann A, et al. Direct delivery of antigens to dendritic cells via antibodies specific for endocytic receptors as a promising strategy for future therapies. Vaccines (Basel) (2016) 4:48. doi:10.3390/vaccines4020008

84. Fan Y, Moon JJ. Nanoparticle drug delivery systems designed to improve cancer vaccines and immunotherapy. Vaccines (Basel) (2015) 3:362–85. doi:10.3390/vaccines3030662

85. Friedman AD, Claypool SE, Liu R. The smart targeting of nanoparticles. Curr Pharm Des (2013) 19:2511–29. doi:10.2174/13816128113199990375

86. Milling L, Yang Y, Irvine DJ. Delivering safer immunotherapies for cancer. Adv Drug Deliv Rev (2017) 114:79–101. doi:10.1016/j.addr.2017.05.011

87. Dhodapkar MV, Szoln M, Zhao B, Wang D, Carvajal RD, Keohan ML, et al. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med (2016) 8:322ra251. doi:10.1126/scitranslmed.3008086

88. Dominguez AL, Lustgarten J. Targeting the tumor microenvironment with anti-neu/anti-CAD4 conjugated nanoparticles for the induction of antitumor immune responses. Vaccine (2010) 28:1383–90. doi:10.1016/j.vaccine.2009.10.153

89. Cruz JJ, Rosalía RA, Kleinovnik JW, Rueda F, Lowik CW, Ossendorp F. Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study. J Control Release (2014) 192:209–18. doi:10.1016/j.jconrel.2014.07.040

90. Maldonado RA, RoMahe RA, Ferrari JD, Zhang AH, Rossi RJ, Kolte PN, et al. Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance. Proc Natl Acad Sci U S A (2015) 112:E156–65. doi:10.1073/pnas.140866111

91. Zhang AH, Rossi RJ, Yoon J, Wang H, Scott DW. Dendritic tolerogenic nanoparticles to induce immunologic tolerance: prevention and reversal of FVII inhibitor formation. Cell Immunol (2016) 301:74–81. doi:10.1016/j.cellimm.2015.11.004

92. Clemente-Casares X, Blanco I, Ambalavanar P, Yamanouchi J, Singh S, Fandos C, et al. Expanding antigen-specific regulatory networks to treat autoimmune disease. Nature (2016) 530:434–40. doi:10.1038/nature16962

93. Lopez MN, Pereda C, Segal G, Munoz L, Aguilera R, Gonzalez FE, et al. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells. J Clin Oncol (2009) 27:945–52. doi:10.1200/JCO.2008.18.0794

94. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 363:411–22. doi:10.1056/NEJMoa1001294

95. Bol KE, Schreibelt G, Gerritsen WR, de Vries II, Fidgert CG. Dendritic cell-based immunotherapy: state of the art and beyond. Clin Cancer Res (2016) 22:1897–906. doi:10.1158/1078-0432.CCR-15-1399

96. Moreau A, Alliot-Licht B, Cuturi MC, Blanchon G. Tolerogenic dendritic cell therapy in organ transplantation. Transpl Int (2017) 30:754–64. doi:10.1111/tri.12889

97. Li X, Yang A, Huang H, Zhang X, Town J, Davis B, et al. Induction of type 2 T helper cell-allergen tolerance by IL-10-differentiated regulatory dendritic cells. J Exp Med (2010) 201:4199–9. doi:10.1084/jem.20090330C

98. Escobar A, Aguirre A, Guzman MA, Gonzalez R, Catalan D, Acuna-Castillo C, et al. Tolerogenic dendritic cells derived from donors with natural rubber latex allergy modulate allergen-specific T-cell responses and IgE production. PLoS One (2014) 9:e85390. doi:10.1371/journal.pone.0085390
108. Raitotach-Regue D, Grau-Lopez L, Naranjo-Gomez M, Ramo-Tello C, Pujol-Borrell R, Martinez-Caceres E, et al. Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients. *Eur J Immunol* (2012) 42:771–82. doi:10.1002/eji.201141835

109. Anderson AE, Swan DJ, Wong OY, Buck M, Eltherington O, Harry RA, et al. Tolerogenic dendritic cells generated with dexamethasone and vitamin D3 regulate rheumatoid arthritis CD4+ T cells partly via transforming growth factor-beta1. *Clin Exp Immunol* (2017) 187:113–23.doi:10.1111/cei.12870

110. Segovia-Gamboa N, Rodriguez-Arellano ME, Rangel-Cruz R, Sanchez-Diaz M, Ramirez-Reyes JC, Faradji R, et al. Tolerogenic dendritic cells induce antigen-specific hyporesponsiveness in insulin- and glutamic acid decarboxylase 65-autoactive T lymphocytes from type 1 diabetic patients. *Clin Immunol* (2014) 154:72–83.doi:10.1016/j.clim.2014.06.009

111. Obreque J, Vega F, Torres A, Cuitino L, Mackern-Oberti JP, Viviani P, et al. Autologous tolerogenic dendritic cells derived from monocytes of systemic lupus erythematosus patients and healthy donors show a stable and immunosuppressive phenotype. *Immunology* (2017) 152:648–59. doi:10.1111/imm.12806

112. Ten Brinke A, Hilkens CM, Cools N, Geissler EK, Hutchinson JA, Humar A, et al. Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies. *PeerJ* (2016) 4:e2300. doi:10.7717/peerj.2300

113. Lord P, Spiering R, Aguillon JC, Anderson AE, Appel S, Benitez-Ribas D, et al. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. *J Exp Med* (2001) 193:233–8. doi:10.1084/jem.193.2.233

114. Joo YB, Park J-E, Choir C-B, Choe J, Jang M, Heo M, et al. Phase 1 study of immunotherapy using autologous loaded dendritic cells in patients with anti-citrullinated peptide antigen positive rheumatoid arthritis. *Proceedings of the ACR/ARHP Annual Meeting, Abstract 946. Boston, MA, USA* (2014).

115. Bell GM, Anderson AE, Diboll J, Reece R, Eltherington O, Harry RA, et al. Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis. *Ann Rheum Dis* (2017) 76:227–34. doi:10.1136/annrheumdis-2015-208456

116. Ezzelebar MB, Raich-Regue D, Lu L, Zahorchak AF, Perez-Gutierrez A, Humar A, et al. Renal allograft survival in nonhuman primates infused with donor antigen-pulsed autologous regulatory dendritic cells. *Am J Transplant* (2017) 17:1476–89. doi:10.1111/ajt.14182

117. Dhodapkar MV, Steinman RM, Kreasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. *J Exp Med* (2001) 193:233–8. doi:10.1084/jem.193.2.233

118. Dhodapkar MV, Steinman RM. Antigen-bearing immature dendritic cells induce peptide-specific CD8+ regulatory T cells in vivo. *Blood* (2002) 100:174–7. doi:10.1182/blood.V100.1.174

119. Okubara K, Garcia-Gonzalez P, Aguillon JC. Gene expression profiling of human monocyte-derived dendritic cells – searching for molecular regulators of tolerogenicity. *Front Immunol* (2015) 6:528. doi:10.3389/fimmu.2015.00528

120. Yan YW, Wang Z, Raimondi G, Wu W, Colvin BL, de Creus A, et al. “Alternatively activated” dendritic cells preferentially secrete IL-10, expand Foxp3+CD4+ T cells, and induce long-term organ allograft survival in combination with CTLA4-Ig. *J Immunol* (2006) 177:5868–77. doi:10.4049/jimmunol.177.9.5868

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationship that could be construed as a potential conflict of interest.

Copyright © 2017 Domogalla, Rostan, Raker and Steinbrink. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.